Skip to main content
星昊医药 logo

星昊医药 — Investor Relations & Filings

Ticker · 920017 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 417 across all filing types
Latest filing 2025-02-20 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920017

About 星昊医药

https://www.sunho.com.cn/

Beijing Sunho Pharmaceutical Co., Ltd. is a technology-driven enterprise specializing in the research, development, manufacturing, and commercialization of advanced pharmaceutical preparations. The company focuses on high-barrier drug delivery systems, including sustained-release, controlled-release, and complex injection technologies. Its core business encompasses the production of a diverse portfolio of chemical drugs and biological products, alongside comprehensive Contract Development and Manufacturing Organization (CDMO) services. Sunho Pharmaceutical operates modern, GMP-compliant production facilities designed to support the entire lifecycle of drug development, from pilot-scale testing to large-scale commercial manufacturing. By leveraging its proprietary formulation platforms, the company provides integrated solutions for complex dosage forms, catering to both domestic and international pharmaceutical markets.

Recent filings

Filing Released Lang Actions
申万宏源证券承销保荐有限责任公司关于北京星昊医药股份有限公司使用银行承兑汇票、信用证、外币、自有资金等方式支付募投项目部分款项并以募集资金等额置换的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from the underwriting and sponsoring institution regarding the company's use of bank acceptance bills, letters of credit, foreign currency, and own funds to pay for part of the fundraising investment projects and the replacement of these payments with an equivalent amount of raised funds. It references regulatory approvals, board and supervisory committee meetings, and compliance with listing rules and continuous supervision measures. The document is not a full financial report but rather a regulatory compliance and verification statement related to fundraising and use of proceeds. It does not contain financial statements or earnings data, nor is it a simple announcement of a report. It is a regulatory compliance filing related to fundraising and use of proceeds, which fits best under Regulatory Filings (RNS) as it does not fit other more specific categories like Capital/Financing Update (CAP) because it is a verification opinion rather than a financing update or announcement. The document length is 4052 characters, which is substantial but not a full annual or interim report. Therefore, the best classification is Regulatory Filings (RNS).
2025-02-20 Chinese
关于使用银行承兑汇票、信用证、外币、自有资金等方式支付募投项目部分款项并以募集资金等额置换的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Beijing Xinghao Pharmaceutical Co., Ltd. regarding the use of bank acceptance bills, letters of credit, foreign currency, and own funds to pay part of the funds for a fundraising investment project and to replace the equivalent amount with raised funds. It details the approval process by the board and supervisory committee, references regulatory approvals, and includes opinions from independent directors and the sponsoring institution. The document is about the management and use of raised funds, specifically a change or update in the use of capital raised through a public stock issuance. It is not a full financial report, audit report, or earnings release, but rather a regulatory announcement about capital usage and compliance with fundraising regulations. The document length is 4038 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, it fits best under Capital/Financing Update (CAP).
2025-02-20 Chinese
第六届董事会第三十七次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 37th meeting of the 6th Board of Directors of Beijing Xinghao Pharmaceutical Co., Ltd. It details the meeting date, attendance, agenda items, voting results, and compliance with legal requirements. There is no indication of financial statements, audit results, or detailed financial data. The document focuses on board decisions and meeting resolutions, which aligns with announcements related to board or management information. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length is short and it is not a report publication announcement or a regulatory filing. Confidence is high due to clear meeting and board resolution content.
2025-02-20 Chinese
第六届董事会第三十六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 36th meeting of the 6th Board of Directors of Beijing Xinghao Pharmaceutical Co., Ltd. It details the meeting date, attendance, agenda items, and voting results. The content focuses on board decisions, specifically about changing the bank branch for a subsidiary's fundraising account and signing a tripartite supervision agreement. There is no financial data, earnings information, or regulatory filings beyond the board meeting resolution. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the company's board of directors.
2025-02-17 Chinese
第六届董事会第三十五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 35th meeting of the 6th Board of Directors of Beijing Xinghao Pharmaceutical Co., Ltd. It details the meeting date, attendance, agenda items, voting results, and authorization decisions. The content focuses on board meeting decisions, specifically about the opening of a special account for raised funds and signing a tripartite supervision agreement. There is no financial data, earnings information, or detailed report content. The document is clearly a Board/Management Information announcement about board meeting resolutions and authorizations, not a full report or financial statement. Therefore, the appropriate classification is MANG (Board/Management Information). The document length is short and it is not an announcement of a report publication but a substantive board meeting resolution announcement, supporting high confidence.
2025-02-10 Chinese
国浩律师（上海）事务所关于北京星昊医药股份有限公司2025年第一次临时股东大会法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the convening, attendance, and voting procedures of the 2025 first extraordinary general meeting (临时股东大会) of Beijing Xinghao Pharmaceutical Co., Ltd. It details the legality and validity of the meeting procedures and voting results. It is not the actual voting results announcement but a legal opinion on the meeting's conduct and validity. The document is relatively short (2206 characters) and focuses on legal compliance and procedural verification for the shareholder meeting. This fits best with the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it relates to the official validation and announcement of shareholder meeting voting results and procedures.
2025-02-06 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.